Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Conference call to discuss “A” corporate update”….

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Apr 30, 2024 6:37pm

65 Views

Post# 36016091

RE:RE:RE:RE:RE:“Conference call to discuss “A” corporate update”….

I think everybody is reading way too much into the wording of "discuss 'a' corporate update". Every quarterly meeting comprises a corporate update and review of financials from the previous quarter. While the specific wording in this case MIGHT hint of a connotation, it also is not incorrect in describing what typically happens.

<< Previous

Bullboard Posts

Next >>

Rock Tech notches official permit for German lithium refinery